1.Tominaga Y, Jorgensen WL.. (2004) General model for estimation of the inhibition of protein kinases using Monte Carlo simulations., 47 (10):[PMID:15115396][10.1021/jm0304358]
2.Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C, Pav S, Proto A, Swinamer A, Tong L, Torcellini C.. (2002) Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate., 45 (14):[PMID:12086485][10.1021/jm020057r]
3.Regan J, Pargellis CA, Cirillo PF, Gilmore T, Hickey ER, Peet GW, Proto A, Swinamer A, Moss N.. (2003) The kinetics of binding to p38MAP kinase by analogues of BIRB 796., 13 (18):[PMID:12941343][10.1016/s0960-894x(03)00656-5]
4.Kroe RR, Regan J, Proto A, Peet GW, Roy T, Landro LD, Fuschetto NG, Pargellis CA, Ingraham RH.. (2003) Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors., 46 (22):[PMID:14561086][10.1021/jm030120s]
5.Klüter S, Grütter C, Naqvi T, Rabiller M, Simard JR, Pawar V, Getlik M, Rauh D.. (2010) Displacement assay for the detection of stabilizers of inactive kinase conformations., 53 (1):[PMID:19928858][10.1021/jm901297e]
6.Liu Y, Gray NS.. (2006) Rational design of inhibitors that bind to inactive kinase conformations., 2 (7):[PMID:16783341][10.1038/nchembio799]
7.PubChem BioAssay data set,
8.Mark Wenlock and Nicholas Tomkinson.Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361]
9.Young RJ, Leeson PD.. (2018) Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations., 61 (15):[PMID:29620890][10.1021/acs.jmedchem.8b00180]
